

III. Response to Restriction Requirement

Applicants hereby elect, without traverse, Group XIII (claims 21-36 and 69), directed to methods of enhancing an immune response in a mammal comprising administering chemokine MCP-4 or a biologically active fraction thereof and an activating agent, wherein the activating agent is a nucleic acid containing an unmethylated CpG motif. Accordingly, please cancel claims 67-68 without prejudice.

IV. Amendment

Kindly amend claim 69 as follows:

69. The method of claim 35, wherein the activating agent is a nucleic acid containing an unmethylated CpG motif.

V. Remarks

Applicants have amended claim 69 so that it does not depend on canceled claim 67. No new matter is introduced by virtue of this amendment.

Attached hereto is a marked-up version of the claims made to claim 69 by the current amendment. The attached page is captioned "**Version with Markings to Show Changes Made.**"

Entry of the amendment and early and favorable action on the merits is requested.

Respectfully,

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC. 20231

on September 19, 2002

Jaye P. McLaughlin
Registered Representative

Jaye P. McLaughlin
Signature

September 19, 2002
Date of Signature

Jaye P. McLaughlin
Jaye P. McLaughlin
Attorney/Agent for Applicant(s)
Registration No.: 41,211
Telephone No.: (908) 298-4299

SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Date: September 19, 2002



CASE SF0896K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

----- X
In re Application of: :
Alain P. Vicari et al. :
For Patent For: : Group Art Unit: 1614
CHEMOKINES AS ADJUVANTS : Date: September 19, 2002
OF IMMUNE RESPONSE :
Serial No.: 09/768,917 :
Filed: January 24, 2001 :
----- X

Customer Service Center
Initial Patent Examination Division
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
SEP 26 2002
TECH CENTER 1600/2900

VERSION WITH MARKINGS TO SHOW CHANGES

IN THE CLAIMS

69. The method of claim [67] 35, wherein the [TLR agonist] activating agent is a nucleic acid containing an unmethylated CpG motif.